RTK mutations and human syndromes: when good receptors turn bad - PubMed (original) (raw)

RTK mutations and human syndromes: when good receptors turn bad

SC Robertson et al. Trends Genet. 2000 Aug.

No abstract available

PubMed Disclaimer

Similar articles

• RTK mutations and human syndromeswhen good receptors turn bad.
  Robertson SC, Tynan JA, Donoghue DJ. Robertson SC, et al. Trends Genet. 2000 Jun;16(6):265-71. doi: 10.1016/s0168-9525(00)02021-7. Trends Genet. 2000. PMID: 10827454 Review.
• Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
  Hechtman JF, Zehir A, Yaeger R, Wang L, Middha S, Zheng T, Hyman DM, Solit D, Arcila ME, Borsu L, Shia J, Vakiani E, Saltz L, Ladanyi M. Hechtman JF, et al. Mol Cancer Res. 2016 Mar;14(3):296-301. doi: 10.1158/1541-7786.MCR-15-0392-T. Epub 2015 Dec 11. Mol Cancer Res. 2016. PMID: 26660078 Free PMC article.
• SH2 domain proteins as high-affinity receptor tyrosine kinase substrates.
  Sierke SL, Koland JG. Sierke SL, et al. Biochemistry. 1993 Sep 28;32(38):10102-8. doi: 10.1021/bi00089a028. Biochemistry. 1993. PMID: 7691170
• Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumors.
  Wang C, Ma Y, Hu Q, Xie T, Wu J, Zeng F, Song F. Wang C, et al. BMC Cancer. 2016 Jul 27;16:545. doi: 10.1186/s12885-016-2608-3. BMC Cancer. 2016. PMID: 27464624 Free PMC article.
• Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.
  Altai M, Orlova A, Tolmachev V. Altai M, et al. Curr Pharm Des. 2014;20(14):2275-92. doi: 10.2174/13816128113196660667. Curr Pharm Des. 2014. PMID: 24025099 Review.

Cited by

• Unliganded EphA3 dimerization promoted by the SAM domain.
  Singh DR, Cao Q, King C, Salotto M, Ahmed F, Zhou XY, Pasquale EB, Hristova K. Singh DR, et al. Biochem J. 2015 Oct 1;471(1):101-9. doi: 10.1042/BJ20150433. Epub 2015 Jul 31. Biochem J. 2015. PMID: 26232493 Free PMC article.
• Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
  Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Wang MH, et al. Acta Pharmacol Sin. 2010 Sep;31(9):1181-8. doi: 10.1038/aps.2010.106. Epub 2010 Aug 9. Acta Pharmacol Sin. 2010. PMID: 20694025 Free PMC article. Review.
• Genome-Wide Identification and Characterization of Tyrosine Kinases in the Silkworm, Bombyx mori.
  He S, Tong X, Han M, Bai Y, Dai F. He S, et al. Int J Mol Sci. 2018 Mar 21;19(4):934. doi: 10.3390/ijms19040934. Int J Mol Sci. 2018. PMID: 29561793 Free PMC article.
• ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.
  Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP. Mahajan K, et al. J Biol Chem. 2014 Oct 10;289(41):28179-91. doi: 10.1074/jbc.M114.584425. Epub 2014 Aug 22. J Biol Chem. 2014. PMID: 25148682 Free PMC article.
• Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
  Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Zeng Q. Al-Aidaroos AQ, et al. J Clin Invest. 2013 Aug;123(8):3459-71. doi: 10.1172/JCI66824. Epub 2013 Jul 8. J Clin Invest. 2013. PMID: 23867504 Free PMC article.

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program